{"nctId":"NCT01324128","briefTitle":"A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients","startDateStruct":{"date":"2011-03"},"conditions":["Chronic Kidney Disease Requiring Chronic Dialysis"],"count":1059,"armGroups":[{"label":"PA21 (2.5 g tablet)","type":"EXPERIMENTAL","interventionNames":["Drug: PA21 (2.5 g tablet containing 500 mg iron)"]},{"label":"Sevelamer carbonate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sevelamer carbonate"]},{"label":"PA21-1 (1.25 g tablet)","type":"OTHER","interventionNames":["Drug: PA21-1 (1.25 g tablet containing 250 mg iron)"]}],"interventions":[{"name":"PA21 (2.5 g tablet containing 500 mg iron)","otherNames":[]},{"name":"Sevelamer carbonate","otherNames":[]},{"name":"PA21-1 (1.25 g tablet containing 250 mg iron)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Dialysis patients with hyperphosphataemia (≥ 1.94 mmol/L; ≥ 6.0 mg/dL)\n* Stable dose of phosphate binder\n* Written informed consent\n\nExclusion Criteria:\n\n* Hyper/hypo calcemia; hyper intact parathyroid hormone (iPTH)\n* Other significant medical conditions\n* Pregnancy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Serum Phosphorus Levels From Week 24 to Week 27","description":"Change in serum phosphorus levels compared between PA21 Maintenance Dose (MD) and PA21-1 Low Dose (LD) in Stage 2 from Week 24 to Week 27","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.23"},{"groupId":"OG001","value":"1.92","spread":"0.23"}]}]}]},{"type":"SECONDARY","title":"Change in Serum Phosphorus Levels From Baseline to Week 12","description":"Change in serum phosphorus levels from baseline to Week 12 in the PA21 group versus the sevelamer group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.19","spread":"0.09"},{"groupId":"OG001","value":"-2.45","spread":"0.11"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":129,"n":707},"commonTop":["Diarrhoea","Hyperphosphataemia","Faeces discoloured","Nausea","Hypertension"]}}}